We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.12B
1-Year Est. Return 144%
This Fund
S&P 500
This Quarter Est. Return
+33.9%
1 Year Est. Return
+144%
3 Year Est. Return
+348.41%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.18B
AUM Growth
+$662M
Cap. Flow
+$335M
Cap. Flow %
15.36%
Top 10 Hldgs %
41.73%
Holding
72
New
21
Increased
12
Reduced
21
Closed
7

Top Buys

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$102M
2
ASND icon
Ascendis Pharma A/S
ASND
+$75.8M
3
SWTX
SpringWorks Therapeutics
SWTX
+$67.9M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$54.9M
5
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$49.1M

Top Sells

Rank Stock Value
1
GBT
Global Blood Therapeutics, Inc.
GBT
+$183M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$64.8M
3
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
+$40.7M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$24.4M
5
FATE icon
Fate Therapeutics
FATE
+$20.4M

Sector Composition

Rank Sector Weight
1 Healthcare 92.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KROS icon
51
Keros Therapeutics
KROS
$197M
$9.35M 0.43%
248,500
-491,028
-66% -$17M
ANAB icon
52
AnaptysBio
ANAB
$1.53B
$9.18M 0.42%
360,000
-312,569
-46% -$7.33M
IPSC icon
53
Century Therapeutics
IPSC
$364M
$9.14M 0.42%
924,641
– –
INZY
54
DELISTED
Inozyme Pharma
INZY
$8.71M 0.4%
3,250,000
– –
TCDA
55
CALL
DELISTED
Tricida, Inc. Common Stock
TCDA
$8.1M 0.37%
+772,700
New +$8.45M
RETA
56
PUT
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$7.96M 0.36%
+316,800
New +$8.78M
DNTH icon
57
Dianthus Therapeutics
DNTH
$5.59B
$7.56M 0.35%
334,938
– –
FULC icon
58
Fulcrum Therapeutics
FULC
$245M
$7.29M 0.33%
900,711
-99,289
-10% -$711K
HOOK
59
DELISTED
HOOKIPA Pharma
HOOK
$6.75M 0.31%
503,600
– –
GHRS icon
60
GH Research
GHRS
$1.91B
$5.8M 0.27%
499,400
– –
ASMB icon
61
Assembly Biosciences
ASMB
$494M
$4.92M 0.23%
250,000
– –
RLMD icon
62
CALL
Relmada Therapeutics
RLMD
$539M
$4.34M 0.2%
+117,200
New +$3.25M
SDGR icon
63
Schrodinger
SDGR
$1.13B
$4.25M 0.19%
170,000
-392,000
-70% -$11.5M
PASG icon
64
Passage Bio
PASG
$14.2M
$1.8M 0.08%
71,953
-44,047
-38% -$1.74M
GRTS
65
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$117K 0.01%
45,500
-1,674,500
-97% -$5.33M
ACAD icon
66
Acadia Pharmaceuticals
ACAD
$4.45B
– –
-1,733,130
Closed -$24.4M
ALNY icon
67
CALL
Alnylam Pharmaceuticals
ALNY
$38.1B
– –
-499,900
Closed -$72.9M
MDGL icon
68
Madrigal Pharmaceuticals
MDGL
$12.4B
– –
-905,000
Closed -$64.8M
PTGX icon
69
PUT
Protagonist Therapeutics
PTGX
$8.58B
– –
-260,500
Closed -$2.06M
SAGE
70
DELISTED
Sage Therapeutics
SAGE
– –
-171,800
Closed -$5.55M
TNYA icon
71
Tenaya Therapeutics
TNYA
$158M
– –
-483,836
Closed -$2.72M
ATYR
72
aTyr Pharma
ATYR
$47.1M
– –
-290,844
Closed -$823K
1 2
3

Similar funds

AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
ACM
AKRE Capital Management Middleburg, Virginia $6.13B AUM 15.27% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
B
Barings Charlotte, North Carolina $6.19B AUM 16.5% 1-Year Est. Return

Deep Track Capital's Q3 2022 Portfolio in Review

As of Q3 2022, Deep Track Capital held 72 positions worth $2.18B, up 44% from $1.52B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Deep Track Capital deployed $335M of net new capital in Q3 2022, opening 21 new positions and adding to 12 existing holdings. Its largest new stake was Horizon Therapeutics Public Limited Company Ordinary Shares: 1,462,800 shares worth $90.5M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 95% a quarter earlier.

On the sell side, the largest reduction was Global Blood Therapeutics, Inc., an estimated $183M trimmed.

  • Deep Track Capital's largest Q3 2022 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 1,462,800 shares worth $90.5M.
  • Deep Track Capital added most to Jazz Pharmaceuticals in Q3 2022, an estimated $54.9M increase.
  • Deep Track Capital's biggest Q3 2022 reduction was Global Blood Therapeutics, Inc., cutting an estimated $183M.
  • Deep Track Capital fully exited Madrigal Pharmaceuticals in Q3 2022, selling an estimated $64.8M.
  • Deep Track Capital's ten largest holdings make up 42% of its $2.18B portfolio in Q3 2022.
  • Deep Track Capital opened 21 new positions and closed 7 in Q3 2022.
  • Deep Track Capital's portfolio value rose 44% quarter-over-quarter to $2.18B.

Based on Deep Track Capital's 13F filing for Q3 2022, filed 14 Nov 2022.